✦ LIBER ✦

The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease

✍ Scribed by J.E. Nash; P. Ravenscroft; S. McGuire; A.R. Crossman; F.S. Menniti; J.M. Brotchie

Book ID: 116458279
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 728 KB
Volume: 188
Category: Article
ISSN: 0014-4886
DOI: 10.1016/j.expneurol.2004.05.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The α2-adrenergic receptor antagonist id

The α2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease

✍ Brian Henry; Susan H. Fox; David Peggs; Alan R. Crossman; Jonathan M. Brotchie 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

The selective mu-opioid receptor antagon

The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease

✍ James B. Koprich; Susan H. Fox; Tom H. Johnston; Allan Goodman; Bertrand Le Bour 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB

## Abstract In Parkinson's disease (PD), dyskinesia develops following long‐term treatment with 3,4‐dihydroxyphenylalanine (L‐dopa). Given the prominent role of the opioid system in basal ganglia function, nonselective opioid receptor antagonists have been tested for antidyskinetic efficacy in the